secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001140361-25-046187
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics partner Viatris files sNDA with FDA for presbyopia treatment
--------------------------------------------------------------------------

- Viatris filed sNDA for Phentolamine Ophthalmic Solution 0.75% to treat presbyopia.
- sNDA supported by positive VEGA-3 Phase 3 results confirming efficacy, safety, durability.
- No assurance FDA will accept sNDA or complete review on anticipated timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125046187/0001140361-25-046187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125046187/ef20061683_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-046187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer